Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protara Therapeutics Inc TARA

Healthcare Biotechnology
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is... see more

Recent & Breaking News (NDAQ:TARA)

Proteon Therapeutics Announces First Quarter 2019 Financial Results

GlobeNewswire May 8, 2019

Mid-Day Market Update: U.S. Stocks Turn Lower; Quantenna Communications Shares Surge

Benzinga.com  March 28, 2019

Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease

GlobeNewswire January 24, 2019

New Research Coverage Highlights Yum! Brands, TELUS, Unifi, Proteon Therapeutics, Sabine Royalty Trust, and Algonquin Power & Utilities — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire November 16, 2018

Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th

GlobeNewswire November 8, 2018

Proteon Therapeutics Announces Third Quarter 2018 Financial Results

GlobeNewswire November 7, 2018

Proteon Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire August 29, 2018

Proteon Therapeutics Announces Second Quarter 2018 Financial Results

GlobeNewswire August 7, 2018

Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

GlobeNewswire June 14, 2018

Proteon Therapeutics Announces First Quarter 2018 Financial Results

GlobeNewswire May 9, 2018

Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

GlobeNewswire May 8, 2018

Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

GlobeNewswire March 14, 2018

Proteon Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire March 6, 2018

Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase

GlobeNewswire March 5, 2018

Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th

GlobeNewswire November 8, 2017

Proteon Therapeutics Announces Third Quarter 2017 Financial Results

GlobeNewswire November 7, 2017

Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017

GlobeNewswire September 5, 2017

Proteon Therapeutics Announces Second Quarter 2017 Financial Results

GlobeNewswire August 7, 2017

Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing

GlobeNewswire August 2, 2017

Proteon Therapeutics Announces $22.0 Million Private Placement

GlobeNewswire June 22, 2017